The US Food and Drug Administration (FDA) has granted 510(k) clearance for the fully automated SeptiCyte RAPID test from Immunexpress. Developed in collaboration with Biocartis Group, the test distinguishes sepsis from non-infectious systemic inflammation in patients who are suspected of having sepsis.

In an interview with PharmaShots, Dr. Murat Kalayoglu, MD, Ph.D., President, and Chief Executive Officer at Cartesian Therapeutics shared his insights on the P-I/IIa study of Descartes-08 for the treatment of the chronic autoimmune disorder generalized myasthenia gravis (gMG) Shots: Descartes-08 is an autologous T-cell product that is engineered with RNA to encode for CAR The company focuses to use […]

Trends are like compasses in that they can show you where opportunity resides. And as every business is influenced by the latest trends, it pays for biopharmaceutical executives to pay attention. In preparing for this year’s annual outlook issue (published in December), Life Science Leader posed some trend-oriented questions to a group of biopharma execs, and here […]